Invion Ltd (ASX:IVX) (OTCMKTS:IVIXF) (FRA:7C8) is a life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan and Japan to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited.
Invion Ltd
ASX:IVX ISIN:AU000000IVX4
News
Invion Limited (ASX:IVX) wishes to announce that RMW Cho Group Limited (RMWC), the licensor of the Photosoft(TM) technology, has successfully completed a Phase II prostate cancer trial (ACTRN12621000633886) using a sublingual (under the tongue) formulation of INV043.
###
529 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 32) (Last 30 Days: 528) (Since Published: 529)